Search research articles
Contact Us
Filters
Showing results (301-310 of 401) with videos related to
Page
of 41
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed, Michael Offin, Kerry Mullaney, et al.
Cancer Research
|
January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 29, 2015
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary
Jennifer J Mueller, Marie Holzapfel, Chan H Han, et al.
JCO Precision Oncology
|
September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets
Maria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
British Journal of Cancer
|
May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Tomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Cancer
|
December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Maria M Rubinstein, David M Hyman, Imogen Caird, et al.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencing
A M Schram, D Reales, J Galle, et al.
JAMA Oncology
|
November 12, 2015
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Kasmintan A Schrader, Donavan T Cheng, Vijai Joseph, et al.
Gynecologic Oncology
|
November 25, 2018
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
Julia L Boland, Qin Zhou, Madhuri Martin, et al.
Page
of 41
Search research articles
Search
Showing results (301-310 of 401) with videos related to
Sort By:
Page
of 41
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed, Michael Offin, Kerry Mullaney, et al.
Cancer Research
|
January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 29, 2015
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary
Jennifer J Mueller, Marie Holzapfel, Chan H Han, et al.
JCO Precision Oncology
|
September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets
Maria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
British Journal of Cancer
|
May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Tomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Cancer
|
December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Maria M Rubinstein, David M Hyman, Imogen Caird, et al.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencing
A M Schram, D Reales, J Galle, et al.
JAMA Oncology
|
November 12, 2015
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Kasmintan A Schrader, Donavan T Cheng, Vijai Joseph, et al.
Gynecologic Oncology
|
November 25, 2018
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
Julia L Boland, Qin Zhou, Madhuri Martin, et al.
Page
of 41